scholarly journals Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells

2017 ◽  
Vol 12 ◽  
pp. 117727191771544 ◽  
Author(s):  
Susanna WL de Geus ◽  
Victor M Baart ◽  
Martin C Boonstra ◽  
Peter JK Kuppen ◽  
Hendrica AJM Prevoo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Plasminogen Activator ◽  
Stromal Cells ◽  
Urokinase Plasminogen Activator ◽  
Receptor Expression ◽  
Prognostic Impact ◽  
Urokinase Plasminogen Activator Receptor ◽  
Neoplastic Cells ◽  
Upar Expression ◽  
Plasminogen Activator Receptor

The urokinase plasminogen activator receptor (uPAR) has been proposed as a potential prognostic factor for various malignancies. The aim of this study is to assess the prognostic value of uPAR expression in neoplastic and stromal cells of patients with pancreatic adenocarcinoma. Urokinase plasminogen activator receptor expression was determined by immunohistochemistry in 122 pancreatic ductal adenocarcinomas. Kaplan-Meier and Cox regression analyses were used to determine the association with survival. Respectively 66%, 82% and 62% of patients with pancreatic cancer expressed uPAR in neoplastic cells, stromal, and in both combined. Multivariate analysis showed a significant inverse association between uPAR expression in both neoplastic and stromal cells and overall survival. The prognostic impact of uPAR in stromal cells is substantial, but not as pronounced as that of uPAR expression in neoplastic cells. This study suggests a role for uPAR as a biomarker to single out higher risk subgroups of patients with pancreatic cancer.

scholarly journals bcl-2Induction of Urokinase Plasminogen Activator Receptor Expression in Human Cancer Cells through Sp1 Activation

2003 ◽  
Vol 279 (8) ◽  
pp. 6737-6745 ◽  
Author(s):  
Daniela Trisciuoglio ◽  
Angela Iervolino ◽  
Antonio Candiloro ◽  
Gabriella Fibbi ◽  
Maurizio Fanciulli ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Plasminogen Activator ◽  
Human Cancer ◽  
Urokinase Plasminogen Activator ◽  
Receptor Expression ◽  
Urokinase Plasminogen Activator Receptor ◽  
Human Cancer Cells ◽  
Plasminogen Activator Receptor

scholarly journals Urokinase Plasminogen Activator Receptor (uPAR) Targeted Therapy with Switchable Chimeric Antigen Receptor T-Cell (sCAR T-Cell) Potential as Pancreatic Cancer Immunotherapy Agent

2020 ◽  
Vol 5 (2) ◽  
pp. 171
Author(s):  
Tungki Pratama Umar ◽  
Muhammad Syahrul Ramadhan ◽  
Nindya Mahfuza
Keyword(s):  
Pancreatic Cancer ◽  
T Cells ◽  
Targeted Therapy ◽  
T Cell ◽  
Plasminogen Activator ◽  
B Cell Lymphoma ◽  
Urokinase Plasminogen Activator ◽  
Urokinase Plasminogen Activator Receptor ◽  
Cell Potential ◽  
Plasminogen Activator Receptor

Pancreatic cancer is the cancer with highest mortality-incidence rate compared with other types of cancer. Most cases can only be treated palliatively. Targeted therapy comes as an alternative to its treatment especially with Switchable CAR T-cells (sCAR T-cells). In pancreatic cancer, urokinase plasminogen activator receptor (uPAR) is a specific target that is excessively expressed in tumor cell microenvironment. Targeted therapy using sCAR T-cells has been proved safe and effective in other types of malignancy such as B cell lymphoma, so it has potency as immunotherapy agent in pancreatic cancer patient.International Journal of Human and Health Sciences Vol. 05 No. 02 April’21 Page: 171-176

Proteomics Reveals Cell‐Surface Urokinase Plasminogen Activator Receptor Expression Impacts Most Hallmarks of Cancer

PROTEOMICS ◽  
2019 ◽  
Vol 19 (21-22) ◽  
pp. 1900026 ◽  
Author(s):  
Seong Beom Ahn ◽  
Abidali Mohamedali ◽  
Dana Pascovici ◽  
Subash Adhikari ◽  
Samridhi Sharma ◽  
...  
Keyword(s):  
Cell Surface ◽  
Plasminogen Activator ◽  
Urokinase Plasminogen Activator ◽  
Receptor Expression ◽  
Hallmarks Of Cancer ◽  
Urokinase Plasminogen Activator Receptor ◽  
Plasminogen Activator Receptor
Sign in / Sign up

Export Citation Format

Share Document